<DOC>
	<DOCNO>NCT01386710</DOCNO>
	<brief_summary>The high-grade malignant brain tumor , glioblastoma multiforme ( GBM ) anaplastic astrocytoma ( AA ) , comprise majority primary brain tumor adult . This group tumor also exhibit aggressive behavior , result median overall survival duration 9-12 month GBM , 3-4 year AA . Initial therapy consist either surgical resection , external beam radiation . All patient experience recurrence first-line therapy , improvement first-line salvage therapy critical enhance quality-of-life prolonging survival . It unknown currently use intravenous ( IV ) therapy even cross blood brain barrier ( BBB ) . The investigator show previous phase I trial single Superselective Intraarterial Cerebral Infusion ( SIACI ) Bevacizumab ( 15mg/kg ) safe effective treatment recurrent GBM . Therefore , phase I/II clinical research trial extension trial investigator seek test hypothesis repeat dose intra-arterial Bevacizumab safe effective treatment recurrent malignant glioma . Additionally investigator analyze combination IA Carboplatin improve treatment response . By achieve aim study investigator also determine IV therapy Bevacizumab IV Carboplatin combine repeat select intra-arterial Bevacizumab plus Carboplatin improve progression free overall survival . The investigator expect project provide important information regard utility repeat SIACI Bevacizumab therapy malignant glioma , may alter way drug deliver investigator patient near future .</brief_summary>
	<brief_title>Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>18 year age old . Documented histologic diagnosis relapse refractory glioblastoma multiforme ( GBM ) , anaplastic astrocytoma ( AA ) anaplastic mixed oligoastrocytoma ( AOA ) . Circumscribed tumor recurrence le 3.5 cm great diameter Patients histologically confirm lowgrade brain tumor relapse enhance tumor MRI evaluate toxicity . Patients must least one confirm evaluable tumor site . Patients must Karnofsky performance status 70 % ( equivalent ECOG level 02 ) Patients must agree use medically effective method contraception period three month treatment period . Women pregnant lactating . Patients significant intercurrent medical psychiatric condition would place increased risk affect ability receive comply treatment posttreatment clinical monitoring . Low GFR history hepatorenal syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GBM</keyword>
	<keyword>AA</keyword>
	<keyword>AO</keyword>
	<keyword>Brain</keyword>
	<keyword>Tumors</keyword>
	<keyword>Malignant</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Multiforme</keyword>
	<keyword>Anaplastic</keyword>
	<keyword>Astrocytoma</keyword>
</DOC>